David M. Mott is an American businessperson who founded MedImmune Ventures, Inc. and who has been at the head of 18 different companies.
He occupies the position of Chairman of Mersana Therapeutics, Inc., Chairman at Epizyme, Inc., Chairman for Ardelyx, Inc., Chairman for Complexa, Inc., Chairman for Cydan II, Inc., Chairman of Cydan LLC (a subsidiary of Cydan II, Inc.), Chairman of Adaptimmune Therapeutics Plc, Chairman of Imara, Inc. and Chairman at Vtesse, Inc.
He is also on the board of 5 other companies.
In the past Mr. Mott was Chairman for Zyngenia, Inc., Chairman for Sagimet Biosciences, Inc., Executive Vice President of AstraZeneca Plc Vice Chairman, President & Chief Executive Officer at MedImmune LLC, President & Chief Executive Officer for MedImmune Ltd. and President for MedImmune Ventures, Inc. (which are all subsidiaries of AstraZeneca Plc), General Partner for New Enterprise Associates LLC, General Partner at NEA Management Co. LLC, Chairman for Conceptis Technologies, Inc., Chairman of Tesaro, Inc., Chairman-Supervisory Board of Prosensa Holding NV, Chairman of Adaptimmune Ltd., Vice President-Health Care Investment Banking at Smith Barney Harris Upham & Co., Inc. and VP-Health Care Investment Banking Group at Harris Upham & Co, Inc.
He received an undergraduate degree from Dartmouth College.